Expand ACAD Menu
ACAD MENU

ACAD Latest Press Releases

-- August 24, 2026 --

European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union Business Wire 3:01 AM

-- August 4, 2026 --

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results Business Wire 4:05 PM

-- July 30, 2026 --

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference Business Wire 5:57 PM

-- July 20, 2026 --

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis Business Wire 9:05 AM

-- July 15, 2026 --

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 Business Wire 4:05 PM

-- July 6, 2026 --

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer Business Wire 9:04 AM

-- June 26, 2026 --

DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP Business Wire 6:49 AM

-- May 6, 2026 --

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance Business Wire 4:05 PM

-- April 30, 2026 --

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career Business Wire 4:05 PM

-- April 28, 2026 --

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Business Wire 4:05 PM

-- April 17, 2026 --

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting Business Wire 9:05 AM

-- April 15, 2026 --

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Business Wire 4:05 PM
Market Data Delayed 15 Minutes